ChemoCentryx, Inc. Appoints Geoffrey M. Parker to Company's Board of Directors
MOUNTAIN VIEW, Calif., Jan. 12 /PRNewswire/ -- ChemoCentryx, Inc., announced today that the Company has appointed Geoffrey M. Parker to the Company's Board of Directors, effective immediately. Mr. Parker is Chief Business Officer of InteKrin Therapeutics, Inc. and previously served as Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. From 1997 to 2009, Mr. Parker directed Goldman Sachs' West Region Healthcare Investment Banking practice, advising many leading biotechnology companies and is well known for his expertise in business and finance within the healthcare sector. In conjunction with Mr. Parker's appointment, Regina Herzlinger will step down from the ChemoCentryx Board. The total number of Board members remains the same.
"I am truly honored and excited about joining the ChemoCentryx Board of Directors," said Geoffrey Parker. "I look forward to working with my fellow board members and the ChemoCentryx management team to bring innovative approaches to patients suffering from inflammatory disorders."
Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional financing, (viii) the timing or likelihood of regulatory filings and approvals, (ix) the availability of corporate partners, (x) the scope of protection ChemoCentryx is able to establish and maintain for intellectual property rights covering its product candidates and technology, (xi) the impact of competitive products and technological changes, (xii) the availability of capital and the cost of capital, (xiii) ChemoCentryx's financial performance, (xiv) developments relating to ChemoCentryx's competitors and other vagaries in the biotechnology industry and (xv) other risks.